T1	Participants 166 213	Non-Hodgkin's Lymphoma Cooperative Study Group.
T2	Participants 556 577	63 evaluable patients
T3	Participants 394 549	70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week).
T4	Participants 674 715	patients receiving no maintenance therapy
T5	Participants 1035 1069	patients on no maintenance therapy
